Research groups

GC27 OncObesity and Metabolism

OncoObesity and Metabolism Group is a basic-clinical multidisciplinary group composed of Postdocs researchers, PhD students, clinicians and laboratory technicians experts in different areas of the Biomedicine field. It is a stable and highly qualified research team that maintains continuous financial support through competitive calls (both public and private) and has a highly productive and qualitative scientific record.

We focus on the study of cellular, molecular and pathophysiological bases that underlie the development and progression of metabolic diseases (such as obesity and diabetes), tumor pathologies and cancer and, on the pathophysiological association and interaction between both pathologies. More specifically, we have a special interest in the study of the function of some endocrine-metabolic factors (hormonal, inflammatory and lipidic systems, chemokines, miRNAs, etc), as well as the molecular and cellular mechanisms underlying in the pathophysiological relationship between obesity and cancer, such as the machineries that control the expression and secretion of inflammatory components (inflammasome), regulators of the senescence-associated secretory phenotype (SASP), factors associated with the regulation of the expression and secretion of miRNAs (DROSHA, DICER, etc.) and extracellular vesicles, as well as machineries and factors that control the splicing process [spliceosome and non-sense mediated mRNA decay (NSMD) and related factors/variants], etc.

We have discovered and patented several cellular and molecular markers associated with metabolic dysregulation processes and with the development and progression of tumour pathologies. Their presence is associated with a higher risk and/or worse prognosis in these patients and which are being studied in our laboratory in collaboration with diverse national and international groups and pharmacological companies. These studies are helping us to demonstrate that the heterogeneity observed in tumours, their phenotypic and clinic variability, their aggressiveness and their resistance to treatments and, as a result, patients’ survival, are strongly influenced by the endocrine-metabolic environment of the patient, but also by the intrinsic characteristics of each tumour [e.g. hormonal-peptide factors and molecular mechanisms dysregulated in tumour cells or in endocrine-metabolic tissues closely related with tumour cells (e.g. adipose tissue)], which altogether can be involved with the initiation and progression  of several types of tumours.

The different research lines of our group have as a common aim: the identification of new diagnostic, prognostic and therapeutic opportunities in the interaction between metabolic dysregulations (mainly obesity) and tumoral pathologies, in order to promote their transfer to the Society and improve the Public Health Systems.

Research Lines

Networks

Keywords

  • Obesity
  • cancer
  • tumor pathologies
  • prostate cancer
  • hepatocellular carcinoma
  • breast cancer
  • bladder cancer
  • pituitary tumors
  • brain tumors
  • diabetes
  • metabolic dysregulations
  • adipose tissue
  • inflammasome
  • miRNAs
  • senescence-associated secretory phenotype (SASP)
  • extracellular vesicles
  • splicing/spliceosome
  • non-sense mediated mRNA decay
  • RNA-exosome
  • telomerase
  • heterogeneity
  • diagnostic biomarkers
  • prognostic biomarkers

Additional Information

5 most relevant publicactions (2017-2019)

1- Hormaechea-Agulla D, Gahete MD, Jiménez-Vacas JM, Gómez-Gómez E, Ibáñez-Costa A, L-López F, Rivero-Cortés E, Sarmento-Cabral A, Valero-Rosa J, Carrasco-Valiente J, Sánchez-Sánchez R, Ortega-Salas R, Moreno MM, Tsomaia N, Swanson SM, Culler MD, Requena MJ, Castaño JP, Luque RM. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness. Molecular Cancer 2017, 16(1):146. IF: 10.679 (Decile 1; Oncology area)

2- Hormaechea-Agulla D, Jiménez-Vacas JM, Gómez-Gómez E, L-López FL, Carrasco-Valiente J, Valero-Rosa J, Moreno MM, Sánchez-Sánchez R, Ortega-Salas R, Gracia-Navarro F, Culler MD, Ibáñez-Costa A, Gahete MD, Requena MJ, Castaño JP, Luque RM. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer. FASEB J 2017, 31(11):4682-4696. IF: 5.595 (Decile 1; Biology area)

3- Gahete MD, Del Rio-Moreno M, Camargo A, Alcala-Diaz JF, Alors-Perez E, Delgado-Lista J, Reyes O, Ventura S, Perez-Martínez P, Castaño JP, Lopez-Miranda J, Luque RM. Changes in Splicing Machinery Components Influence, Precede, and Early Predict the Development of Type 2 Diabetes: From the CORDIOPREV Study. EBioMedicine 2018, 3964(18)30479-1. IF: 6.68. (Decil 1e; Medicine, Research & Experimental area).

4- Vázquez-Borrego MC, L-López F, Gálvez-Moreno MA, Fuentes-Fayos AC, Venegas-Moreno E, Herrera-Martínez AD, Blanco-Acevedo C, Solivera J, Landsman T, Gahete MD, Soto-Moreno A, Culler MD, Castaño JP, Luque RM. A new generation somatostatin-dopamine analogue exerts potent antitumoral actions on pituitary neuroendocrine tumor cells. Neuroendocrinology 2019, 110(1-2):70-82. FI: 6.804. (Decile 1; Endocrinology and Metabolism area)

5- Jiménez-Vacas JM, Gómez-Gómez E, Montero-Hidalgo AJ, Herrero-Aguayo V, L-López F, Sánchez-Sánchez R, Guler I, Blanca A, Méndez-Vidal MJ, Carrasco J, Lopez-Miranda J, Requena-Tapia MJ, Castaño JP, Gahete MD, Luque RM. Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer. J Clin Med. 2019; 8(12). IF: 5.688 (Decile 1; Medicine, General and Internal).

Ongoing projects

1. Identification of novel endocrine-metabolic factors implicated in the pathophysiological interaction between obesity and the development and aggressiveness of prostate cancer. PI: Raúl Miguel Luque Huertas /Co-PI: Manuel D. Gahete Ortiz. Programa FEDER de la Junta de Andalucía 2014-2020; University Of Córdoba; Ref: 27416. 2019-2022. 49.500 €.

2. Therapeutic role of bioactive compounds of extra virgin olive oil in the pathological association of prostate cancer and obesity (PI-0152-2019). PI: Antonio José León González. Proyectos de Investigación en Salud. Consejería de Salud y Familias de la Junta de Andalucía. 2019-2022. 68.994,25 €.

3. Clinical-Molecular evolution of inflammatory, apoptotic and hormonal markers after bariatric surgery: metabolic changes, comorbidities improvements, splicing, prediction of complications and subjacent mechanisms (PI-0038-2019). PI: Aura Dulcinea Herrera Martínez. Proyectos de Investigación en Salud. Consejería de Salud y Familias de la Junta de Andalucía. 2019-2022. 69.000 €.

4. Spliceosomic strategy to improve the diagnostic, classification and treatment of pancreatic neuroendocrine tumors. G1909. PI: Justo P Castaño Fuentes. Beca GETNE 2019. 2020-2022. 60.000 €.

5. Telotristat Etiprate: utility on the mesenteric fibrosis and cardiac illness for carcinoid. Autocrine/paracrine effect of the serotonin in the fibrosis and carcinoid syndrome. PI: Aura Dulcinea Herrera Martínez. Beca GETNE Junior 2019. 2020-2022. 20.000 €.

6. Identification of new diagnostic, prognostic and/or therapeutic targets associated with the dysregulation of splicing mechanisms in neuroendocrine pituitary tumors. PI: Manuel D. Gahete Ortiz. Fundación de la Sociedad Española de Endocrinología y Nutrición (FSEEN). 2020-2021. 7.500 €.

7. Clinical-molecular changes after bariatric surgery: role of vitamin D in the reversion of metabolic comorbidities associated to the obesity. PI: Aura Dulcinea Herrera Martínez. Fundación Española de Investigación Ósea y del Metabolismo Mineral (FEIOMM). 2020-2021. 7.000 €

8. Molecular and functional characterization of bladder cancer and castration-resistant prostate cancer: search of novel therapies. PI: Raúl Miguel Luque Huertas /Co-PI: Manuel D. Gahete Ortiz. Eli Lilly & Company. 2019-2020. 74.800 €.

9. Spliceosomic strategy in NETs for the improvement of diagnostic, classification and treatment. FERP2019. PI: Justo P Castaño Fuentes. Fundación Eugenio Rodríguez Pascual 2019. 2019-2020. 7.000 €

10. Analysis of the in vitro combination of trastuzumab and lirilumab in breast cancer. Involvement of alternative splicing processes. PI: Cristina Morales Estévez / Co-PI: Manuel D. Gahete Ortiz. Sociedad Española de Oncología Médica (Beca FSEOM/BMS - Proyectos de investigación traslacional en Inmuno-Oncología 2018). 2019-2020. 40.000€.

9. Ghrelin-O-acil-Transferase (GOAT): New Biomarker for the screening of prostate cancer. (DTS18/00131). PI: Raúl Miguel Luque Huertas. Instituto de Salud Carlos III. Modalidad Proyectos de Desarrollo Tecnológico en Salud. 2018-2020. 88.550€.

11. New molecular mechanisms in the pathological interaction between obesity and prostate cancer: alternative splicing and miRNAs as potential biomarkers and therapeutic targets. (FIS Project PI16/00264). PI: Raúl Miguel Luque Huertas. Instituto de Salud Carlos III. 2017-2020. 212.052,50€.

12. Involvement of new molecular and endocrine-metabolic factors in the pathological interaction between obesity and the development of hepatocarcinoma. (FIS Project PI17/02287). PI: Manuel David Gahete Ortiz. Instituto de Salud Carlos III. 2018-2020. 194.507,50€.

13. Ghrelin-O-aciltransferase (GOAT):  new biomarker for prostate cancer (FIPSE Project 3188-17). PI: Raúl M Luque. Fundación para la Innovación y la Prospectiva en Salud en España. 2018-2019. 30.000€.

14. Diagnosis and personalized postoperative prognosis of human gliomas using a new interactive approach. PI-0143-2016. PI: Juan Solivera Vela. Consejería de Salud (Junta de Andalucía). 2017-2019. 46.970,42 €.

15. Acquisition of scientific-technical equipment: polyvalent system of genomic analysis of last generation (EQC2018-005254-P). PI: Raúl Miguel Luque Huertas. Ministry of Science, Innovation and Universities. Spanish Plan I+D+I 2017-2020 and European foundation for Regional development (FEDER). 2019. 372.930€.

Patents

1. Transgenic mouse "rGHp-Cre", which allows the selective alteration of specific genes (elimination or overexpression) in the somatotropic cells of the pituitary gland using the "Cre / LoxP" system. Luque RM, Amargo G, Ishii S, Lobe C, Franks R, Kiyokawa H, Kineman RD.

2. Ghrelin Variants and its use. Luque RM, Castaño JP, Gahete MD, Gracia-Navarro F, Martínez-Fuentes AJ, Córdoba-Chacón J, Benito P, Kineman RD. P201030905.

3. Ghrelin-O-acyltransferase (GOAT) and its use. Luque RM, Castaño JP, Gahete MD, Hormaechea-Agulla D, Requena-Tapia MJ, Gómez-Gómez E, Carrasco-Valiente J, Ibáñez-Costa A, Moreno MM, Valero-Rosa J. P201531731 - PCT/ES2016/070844

4. Non-invasive diagnostic method for cancer. Luque RM, Castaño JP, Gahete MD, Ibáñez-Costa A, Hormaechea-Agulla D, Jiménez-Vacas JM, Sarmento-Cabral A, L-López F, Requena-Tapia MJ, Gómez-Gómez E, Carrasco-Valiente J.P201631606 - PCT/ES2017/070797

5. Peptides derived from the truncated somatostatin receptor sst5TMD4 as biomarkers and therapeutic targets in tumor pathologies.Luque RM, Castaño JP, Gahete MD, del Río-Moreno M, Alors-Pérez E. P201730702 - PCT/ES2018/070361

6. Method for the prediction and prognostic of the development of type 2 diabetes mellitus. Luque RM, Gahete MD, López-Miranda J, Perez-Martínez P, Delgado-Lista J, García-Ríos A, Alcalá-Díaz JF, Yubero-Serrano E, Camargo-García A, del Río-Moreno M, Alors-Pérez E, Castaño JP, Ventura-Soto S, Reyes-Pupo O. P201831095

7. Method for the diagnosis, prognosis and treatment of neuroendocrine tumors. Luque RM, Castaño JP, Gahete MD, Pedraza-Arévalo S, del Río-Moreno M, Alors-Pérez E, Gálvez-Moreno MA, Herrera-Martínez A, Serrano-Blanch R. P201831039

8. Method for the diagnosis and prognosis of the development of prostate cancer. Luque RM, Gahete MD, Castaño JP, Jiménez-Vacas JM, Sarmento-Cabral A, L-López F, Requena-Tapia MJ, Gómez-Gómez E, Carrasco-Valiente J. P201930104

9. Method of obtaining useful data for the diagnosis, stratification and / or follow-up of patients with rheumatoid arthritis. Luque RM, López-Pedrera R, Perez-Sanchez C, Collantes- Estevez E, Ortega -Castro R, Castaño JP, Ibáñez-Costa A, Pedraza-Arévalo S, del Río-Moreno M, Barbarroja-Puerto N, Jimenez-Gomez Y. P201930123

10. Method for the diagnosis and prognosis of the development of brain tumors. Luque RM, Gahete MD, Fuentes-Fayos AC, Castaño JP, Ibañez-Costa A, Vazquez-Borrego MC, Lopez-Lopez F, Blanco-Acebedo C, Solivera-Vela J, Toledano-Delgado A, Galvez-Moreno MA. P201931147

GC27 OncObesity and Metabolism

Principal Investigator
Raúl Miguel Luque Huertas

Co-Principal Investigator
Manuel David Gahete Ortiz

Senior Reseacher
Antonio Jesús Martínez Fuentes

Post-Doctoral Researchers
Antonio José León González
Mercedes del Río Moreno
María del Carmen Vázquez Borrego
Enrique Gómez Gómez
André Morais Sarmento Borges Cabral

Pre-Doctoral Researchers
Juan Manuel Jiménez Vacas
Emilia María Alors Pérez
Vicente Herrero Aguayo
Prudencio Sáez Martínez
Juan Luis López Cánovas
Rafael Sánchez Sánchez
María Teresa Sánchez Medianero
Álvaro Toledano Borrego
Antonio Jesús Montero Hidalgo
Jesús Miguel Pérez Gómez

Technical Staff
Fernando López López

Students
Jesús Delgado Luque
Trinidad Moreno Montilla
Helena García Fernández

Projects

Active projects

National

Identification of novel endocrine-metabolic factors implicated in the pathophysiological interaction between obesity and the development and aggressiveness of prostate cancer. Programa FEDER de la Junta de Andalucía 2014-2020; University Of Córdoba (Ref: 27416). PI: Luque-Huertas RM / Gahete-Ortiz MD. 

Therapeutic role of bioactive compounds of extra virgin olive oil in the pathological association of prostate cancer and obesity. Proyectos de Investigación en Salud. Consejería de Salud y Familias de la Junta de Andalucía (PI-0152-2019). PI: León-González AJ.

Clinical-Molecular evolution of inflammatory, apoptotic and hormonal markers after bariatric surgery: metabolic changes, comorbidities improvements, splicing, prediction of complications and subjacent mechanisms. Proyectos de Investigación en Salud. Consejería de Salud y Familias de la Junta de Andalucía (PI-0038-2019). PI: Herrera-Martínez AD.

Spliceosomic strategy in NETs for the improvement of diagnostic, classification and treatment. Fundación Eugenio Rodríguez Pascual 2019. FERP2019. PI: Castaño-Fuentes JP.

Analysis of the in vitro combination of trastuzumab and lirilumab in breast cancer. Involvement of alternative splicing processes. Sociedad Española de Oncología Médica. Proyectos de investigación traslacional en Inmuno-Oncología 2018. Beca FSEOM/BMS. PI: Morales-Estévez C / Gahete-Ortiz MD.

Ghrelin-O-acil-Transferase (GOAT): New Biomarker for the screening of prostate cancer. Instituto de Salud Carlos III. Modalidad Proyectos de Desarrollo Tecnológico en Salud (DTS18/00131). 2018-2020. 88.550€. PI: Raúl Miguel Luque Huertas.

New molecular mechanisms in the pathological interaction between obesity and prostate cancer: alternative splicing and miRNAs as potential biomarkers and therapeutic targets. Instituto de Salud Carlos III (FIS Project PI16/00264).  PI: Luque-Huertas RM.

Involvement of new molecular and endocrine-metabolic factors in the pathological interaction between obesity and the development of hepatocarcinoma. Instituto de Salud Carlos III (FIS Project PI17/02287). 2018-2020. 194.507,50€. PI: Manuel David Gahete Ortiz.

Ghrelin-O-aciltransferase (GOAT): new biomarker for prostate cancer. Fundación para la Innovación y la Prospectiva en Salud en España (FIPSE Project 3188-17). PI: Luque-Huertas RM.

Diagnosis and personalized postoperative prognosis of human gliomas using a new interactive approach. Consejería de Salud, Junta de Andalucía (PI-0143-2016). PI: Solivera-Vela J.

Acquisition of scientific-technical equipment: polyvalent system of genomic analysis of last generation. Ministry of Science, Innovation and Universities. Spanish Plan I+D+I 2017-2020 and European foundation for Regional development (FEDER). (EQC2018-005254-P). PI: Luque-Huertas RM.

Finished projects

New molecular mechanisms in the pathological interaction between obesity and prostate cancer: alternative splicing and miRNAs as potential biomarkers and therapeutic targets. (FIS Project PI16/00264). PI: Raúl Miguel Luque Huertas. Instituto de Salud Carlos III. 2017-2019. 212.052,50€.

Ghrelin-O-acil transferase (GOAT): new biomarker for prostate cancer. (FIPSE Project 3188-17). PI: Raúl Miguel Luque Huertas. 2018-2019. 30.000€.

GOAT (Ghrelin-O-acil transferase): new biomarker for prostate cancer screening (Proyecto Caixa-Impulse CI17-00015). PI: Raúl Miguel Luque Huertas. 2017-2018. 70.000€.

 

Publications

Main Publications 2019

Jiménez-Vacas JM, Gómez-Gómez E, Montero-Hidalgo AJ, Herrero-Aguayo V, L-López F, Sánchez-Sánchez R, Guler I, Blanca A, Méndez-Vidal MJ, Carrasco J, Lopez-Miranda J, Requena-Tapia MJ, Castaño JP, Gahete MD, Luque RM. Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer. JOURNAL OF CLINICAL MEDICINE.  2019 Nov 22;8(12). pii: E2056. doi: 10.3390/jcm8122056.
IF: 5,583
Q: 1 D: 1

Del Rio-Moreno M, Alors-Perez E, De Souza PB, Prados-Gonzalez ME, Castano JP, Luque RM, Gahete MD; Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types. TRANSLATIONAL RESEARCH.  2019 Sep;211:147-160. doi: 10.1016/j.trsl.2019.02.013.
IF: 4,915
Q: 1 D: 1

Jimenez-Vacas JM, Herrero-Aguayo V, Gomez-Gomez E, Leon-Gonzalez AJ, Saez-Martinez P, Alors-Perez E, Fuentes-Fayos AC, Martinez-Lopez A, Sanchez-Sanchez R, Gonzalez-Serrano T, Lopez-Ruiz DJ, Requena-Tapia MJ, Castano JP, Gahete MD, Luque RM; Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. TRANSLATIONAL RESEARCH. 212. (89-103). DOI: 10.1016/j.trsl.2019.07.001.
IF: 4,915
Q: 1 D: 1

Vazquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortes E, Dios E, Moreno-Moreno P, Madrazo-Atutxa A, Remon P, Solivera J, Wildemberg LE, Kasuki L, Lopez-Fernandez JM, Gadelha MR, Galvez-Moreno MA, Soto-Moreno A, Gahete MD, Castano JP, Luque RM; Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features. CANCERS. 2019 Sep 26;11(10). pii: E1439. doi: 10.3390/cancers11101439.
IF: 6,162
Q: 1

Gomez-Gomez, E; Jimenez-Vacas, JM; Pedraza-Arevalo, S; Lopez-Lopez, F; Herrero-Aguayo, V; Hormaechea-Agulla, D; Valero-Rosa, J; Ibanez-Costa, A; Leon-Gonzalez, AJ; Sanchez-Sanchez, R; Gonzalez-Serrano, T; Requena-Tapia, MJ; Castano, JP; Carrasco-Valiente, Gahete MD, Luque RM; Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer. JOURNAL OF CLINICAL MEDICINE. 2019 Sep 6;8(9). pii: E1400. doi: 10.3390/jcm8091400.
IF: 5,688
Q: 1 D: 1

Other publications 2019

Thomas PB, Seim I, Jeffery PL, Gahete MD, Maugham M, Crisp GJ, Stacey A, Shah ET, Walpole C, Whiteside EJ, Nelson CC, Herington AC, Luque RM, Veedu RN, Chopin LK. The long non-coding RNA GHSROS facilitates breast cancer cell migration and orthotopic xenograft tumour growth. INTERNATIONAL JOURNAL OF ONCOLOGY. 2019 Dec;55(6):1223-1236. doi: 10.3892/ijo.2019.4891.
IF: 3,571
D: 1

Quintana-Navarro GM, Alcala-Diaz JF, Lopez-Moreno J, Perez-Corral I, Leon-Acuña A, Torres-Peña JD, Rangel-Zuñiga OA, Arenas de Larriva AP, Corina A, Camargo A, Yubero-Serrano EM, Rodriguez-Cantalejo F, Garcia-Rios A, Luque RM, Ordovas JM, Perez-Martinez P, Lopez-Miranda J, Delgado-Lista J. Long-term dietary adherence and changes in dietary intake in coronary patients after intervention with a Mediterranean diet or a low-fat diet: the CORDIOPREV randomized trial. EUROPEAN JOURNAL OF NUTRITION. 2019 Jul 24. doi: 10.1007/s00394-019-02059-5.
IF: 4,449
D: 1

Hoa O, Lafont C, Fontanaud P, Guillou A, Kemkem Y, Kineman RD, Luque RM, Fiordelisio Coll T, Le Tissier P, Mollard P. Imaging and Manipulating Pituitary Function in the Awake Mouse. ENDOCRINOLOGY. 2019 Oct 1;160(10):2271-2281. doi: 10.1210/en.2019-00297.
IF: 3,800
D: 1

Herrera-Martínez AD, Pedraza-Arevalo S, L-López F, Gahete MD, Gálvez-Moreno MA, Castaño JP, Luque RM. Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?. THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2019 Jan 1;104(1):57-73. doi: 10.1210/jc.2018-01455.
Q: 1

Remacha L, Pirman D, Mahoney CE, Coloma J, Calsina B, Curras-Freixes M, Leton R, Torres-Perez R, Richter S, Pita G, Herraez B, Cianchetta G, Honrado E, Maestre L, Urioste M, Aller J, Garcia-Uriarte O, Galvez MA, Luque RM, Lahera M, Moreno-Rengel C, Eisenh; Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas. AMERICAN JOURNAL OF HUMAN GENETICS. 2019 Apr 4;104(4):651-664. doi: 10.1016/j.ajhg.2019.02.017
IF: 9,924
D: 1

Olarescu NC, Perez-Rivas LG, Gatto F, Cuny T, Tichomirowa MA, Tamagno G, Gahete MD; Aggressive and Malignant Prolactinomas. NEUROENDOCRINOLOGY. 2019;109(1):57-69. doi: 10.1159/000497205.
IF: 6,804
D: 1

Biagetti B, Herance JR, Ferrer R, Aulinas A, Palomino-Schatzlein M, Mesa J, Castano JP, Luque RM, Simo R; Metabolic Fingerprint of Acromegaly and Its Potential Usefulness in Clinical Practice. JOURNAL OF CLINICAL MEDICINE. 2019 Sep 26;8(10). pii: E1549. doi: 10.3390/jcm8101549.
IF: 5,688
Q:1 D:1

Vazquez-Borrego MC, Fuentes-Fayos AC, Herrera-Martinez AD, L-Lopez F, Ibanez-Costa A, Moreno-Moreno P, Alhambra-Exposito MR, Barrera-Martin A, Blanco-Acevedo C, Dios E, Venegas-Moreno E, Solivera J, Gahete MD, Soto-Moreno A, Galvez-Moreno MA, Castano JP, Luque RM; Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2019 Aug 1;104(8):3501-3513. doi: 10.1210/jc.2019-00056.
IF: 5,605
Q: 1

del Rio-Moreno M, Alors-Perez E, Gonzalez-Rubio S, Ferrin G, Reyes O, Rodriguez-Peralvarez M, Sanchez-Frias ME, Sanchez-Sanchez R, Ventura S, Lopez-Miranda J, Kineman RD, de la Mata M, Castano JP, Gahete MD, Luque RM; Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2019 Aug 1;104(8):3389-3402. doi: 10.1210/jc.2019-00021.
IF: 5,605
Q; 1

Herrera-Martinez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Moreno MAG, Luque RM, Castano JP, de Herder WW, Feelders RA; Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. DRUGS. 2019 Jan;79(1):21-42. doi: 10.1007/s40265-018-1033-0.
IF: 4,993
Q: 1

Herrera-Martinez AD, van den Dungen R, Dogan-Oruc F, van Koetsveld PM, Culler MD, de Herder WW, Luque RM, Feelders RA, Hofland LJ; Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors. ENDOCRINE-RELATED CANCER. 2019 Jun;26(6):585-599. doi: 10.1530/ERC-19-0086.
IF: 4,774
Q; 1

Frantzi M, Gomez EG, Pedregosa AB, Rosa JV, Latosinska A, Culig Z, Merseburger AS, Luque RM, Tapia MJR, Mischak H, Valiente JC; CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. BRITISH JOURNAL OF CANCER. 2019 Jun;120(12):1120-1128. doi: 10.1038/s41416-019-0472-z.
IF: 5,416
Q: 1

Gomez-Gomez E, Carrasco-Valiente J, Campos-Hernandez JP, Blanca-Pedregosa AM, Jimenez-Vacas JM, Ruiz-Garcia J, Valero-Rosa J, Luque RM, Requena-Tapia MJ; Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2019 Feb;23(2):934-942. doi: 10.1111/jcmm.13994.
IF: 4,658
Q: 1

Venegas-Moreno E, Flores-Martinez A, Dios E, Vazquez-Borrego MC, Ibanez-Costa A, Madrazo-Atutxa A, Japon MA, Castano JP, Luque RM, Cano DA, Soto-Moreno A; E-cadherin expression is associated with somatostatin analogue response in acromegaly. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE.2019 May;23(5):3088-3096. doi: 10.1111/jcmm.13851.
IF: 4,658
Q: 1

Borque-Fernando A, Rubio-Briones J, Esteban LM, Dong Y, Calatrava A, Gomez-Ferrer A, Gomez-Gomez E, Fabra JMG, Rodriguez-Garcia N, Gonzalez PAL, Garcia-Rodriguez J, Rodrigo-Aliaga M, Herrera-Imbroda B, Soto-Villalba J, Martinez-Breijo S, Hernandez-Canas V; Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance. PROSTATE CANCER AND PROSTATIC DISEASES. 2019 Mar;22(1):84-90. doi: 10.1038/s41391-018-0074-5. 
IF: 4,6
Q: 1

Leon-Acuna A, Torres-Pena JD, Alcala-Diaz JF, Vals-Delgado C, Roncero-Ramos I, Yubero-Serrano E, Tinahones FJ, Castro-Clerico M, Delgado-Lista J, Ordovas JM, Lopez-Miranda J, Perez-Martinez P; Lifestyle factors modulate postprandial hypertriglyceridemia: From the CORDIOPREV study. ATHEROSCLEROSIS. 2019 Nov;290:118-124. doi: 10.1016/j.atherosclerosis.2019.09.025
IF: 4,255
Q: 1

Coelho MCA, Vasquez ML, Wildemberg LE, Vazquez-Borrego MC, Bitana L, Camacho AHD, Silva D, Ogino LL, Ventura N, Sanchez-Sanchez R, Chimelli L, Kasuki L, Luque RM, Gadelha MR; Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles. SCIENTIFIC REPORTS. 2019 Feb 4;9(1):1122. doi: 10.1038/s41598-018-37692-3.
IF: 4,011
Q: 1

Gomez-Delgado F, Alcala-Diaz JF, Leon-Acuna A, Lopez-Moreno J, Delgado-Lista J, Gomez-Marin B, Roncero-Ramos I, Yubero-Serrano EM, Rangel-Zuniga OA, Vals-Delgado C, Luque RM, Ordovas JM, Lopez-Miranda J, Perez-Martinez P; Apolipoprotein E genetic variants interact with Mediterranean diet to modulate postprandial hypertriglyceridemia in coronary heart disease patients: CORDIOPREV study. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2019 Aug;49(8):e13146. doi: 10.1111/eci.13146.
IF: 2,784

Q: 1

Soriano S, Castellano-Munoz M, Rafacho A, Alonso-Magdalena P, Marroqui L, Ruiz-Pino A, Bru-Tari E, Merino B, Irles E, Bello-Perez M, Iborra P, Villar-Pazos S, Vettorazzi JF, Montanya E, Luque RM, Nadal A, Quesada I; Cortistatin regulates glucose-induced electrical activity and insulin secretion in mouse pancreatic beta-cells. MOLECULAR AND CELLULAR ENDOCRINOLOGY. 2019 Jan 5;479:123-132. doi: 10.1016/j.mce.2018.09.009.
IF: 3,693
Q: 2

Blanca A, Sanchez-Gonzalez A, Requena MJ, Carrasco-Valiente J, Gomez-Gomez E, Cheng L, Cimadamore A, Montironi R, Lopez-Beltran A; Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer. APMIS. 2019 Aug;127(8):545-553. doi: 10.1111/apm.12973.
IF: 2,225
Q: 2

Fuentes-Fayos AC, Garcia-Martinez A, Herrera-Martinez AD, Jimenez-Vacas JM, Vazquez-Borrego MC, Castano JP, Pico A, Gahete MD, Luque RM; Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors. MINERVA ENDOCRINOLOGICA. 2019 Jun;44(2):109-128. doi: 10.23736/S0391-1977.19.02970-5. 
IF: 1,817
Q: 4

Juárez-Soto A, Garín-Ferreira JM, Rodríguez-Fernández A, Tirado-Hospital JL, González-Serrano MT, Moreno-Jiménez J, Medina-López R, Baena-González V. Diagnosis of metastasis in castration-resistant prostate cancer patients: decision algorithm in imaging tests. ACTAS UROLOGICAS ESPANOLAS. 2019 Mar;43(2):55-61. doi: 10.1016/j.acuro.2018.05.011
IF: 1,136
D: 2

Gomez Gomez E, Salamanca Bustos JJ, Carrasco Valiente J, Fernandez Rueda JL, Blanca A, Valero Rosa J, Bravo Arrebola I, Marquez López J, Jimenez Vacas JM, Luque R, Requena Tapia MJ. Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL. BRITISH MEDICAL JOURNAL OPEN. 2019 Nov 12;9(11):e031032. doi: 10.1136/bmjopen-2019-031032.
IF: 2,376
D: 2

Gómez-Gómez E, Carrasco-Valiente J, Campos-Hernández JP, Blanca-Pedregosa AM, Jiménez-Vacas JM, Ruiz-García J, Valero-Rosa J, Luque RM, Requena-Tapia MJ. Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2019 Feb;23(2):934-942. doi: 10.1111/jcmm.13994.
IF: 4,658
Q: 1

Main Publications 2018

Gahete MD, Del Rio-Moreno M, Camargo A, Alcala-Diaz JF, Alors-Perez E, Delgado-Lista J, Reyes O, Ventura S, Perez-Martínez P, Castaño JP, Lopez-Miranda J, Luque RM. Changes in Splicing Machinery Components Influence, Precede, and Early Predict the Development of Type 2 Diabetes: From the CORDIOPREV Study. EBioMedicine 2018, 3964(18)30479-1.
IF: 6.680
Q: 1   D: 1

Vázquez-Borrego MC, Fuentes-Fayos AC, Gahete MD, Castaño JP, Kineman RD, Luque RM. The pituitary gland is a novel major site of action of metformin in non-human primates: A potential path to expand and integrate its metabolic actions. Cell Physiol Biochem 2018, 49(4):1444-1459.

IF: 5.500
Q: 1   D: 1

Gómez-Gómez E, Jiménez-Vacas JM, Carrasco-Valiente J, Herrero-Aguayo V, Blanca-Pedregosa AM, León-González AJ, Valero-Rosa J, Fernández-Rueda JL, González-Serrano T, López-Miranda J, Gahete MD, Castaño JP, Requena-Tapia MJ, Luque RM. Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer. J Cell Mol Med 2018, 22(11):5688-5697.
IF: 4.658
Q: 1

Herrera-Martínez AD, Gahete MD, Sánchez-Sánchez R, Alors-Perez E, Pedraza-Arevalo S, Serrano-Blanch R, Martínez-Fuentes AJ, Gálvez-Moreno MA, Castaño JP, Luque RM. Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors. Clin Transl Gastroenterol 2018, 9(10):196.
IF: 4.803
Q: 1

Gahete MD, Jimenez-Vacas JM, Alors-Perez E, Herrero-Aguayo V, Fuentes-Fayos AC, Pedraza-Arevalo S, Castano JP, Luque RM; Mouse models of endocrine tumors. J Endocrinol. 2018 Nov 1. pii: JOE-18-0571.R1.
IF: 4,381
Q: 1

Alhambra-Expósito MR, Ibáñez-Costa A, Moreno-Moreno P, Rivero-Cortés E, Vázquez-Borrego MC, Blanco-Acevedo C, Toledano-Delgado Á, Lombardo-Galera MS, Vallejo-Casas JA, Gahete MD, Castaño JP, Gálvez MA, Luque RM. Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas. Sci Rep 2018, 8(1):6173.
IF: 4.011
Q: 1

Other Publications 2018

Venegas-Moreno E, Vazquez-Borrego MC, Dios E, Gros-Herguido N, Flores-Martinez A, Rivero-Cortes E, Madrazo-Atutxa A, Japon MA, Luque RM, Castano JP, Cano DA, Soto-Moreno A. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly. J Cell Mol Med 2018, 22(3)1640-1649.
IF: 4.658
Q: 1

Alves-Coelho MC, Vasquez ML, Wildemberg LE, Vazquez-Borrego MC, Bitana L, Camacho AHD, Silva D, Ogino LL, Ventura N, Chimelli L, Luque RM, Kasuki L, Gadelha MR. Molecular evidence and clinical importance of beta-arrestins expression in patients with a cromegaly. J Cell Mol Med 2018, 22(4)2110-2116.
IF: 4.658
Q: 1

Herrera-Martínez AD, Gahete MD, Pedraza-Arévalo S, Sánchez-Sánchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Gálvez-Moreno MA, Castaño JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Endocrine 2018, 59(2):426-437.
IF: 3.296
Q: 2   

Vázquez-Borrego MC, Gahete MD, Martínez-Fuentes AJ, Fuentes-Fayos AC, Castaño JP, Kineman RD, Luque RM. Review. Multiple signaling pathways convey central and peripheral signals to regulate pituitary function: lessons from human and non-human primate models. Mol Cell Endocrinol 2018, 463:4-22.
IF: 3.693
Q: 2        

Rincón-Fernández D, Culler MD, Tsomaia N, Moreno-Bueno G, Luque RM, Gahete MD, Castaño JP. In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines. Carcinogenesis 2018, 39(3):447-457.
IF: 4.004
Q: 2   

Luque RM, Kineman RD. Neuronostatin exerts actions on pituitary that are unique from its sibling peptide somatostatin. J Endocrinol 2018, 237(3):217-227.
IF: 4.381
Q: 1

Pedraza-Arevalo S, Gahete MD, Alors-Perez E, Luque RM, CastanoJP. Multilayered heterogeneity as an intrinsic hallmark of neuroendocrinetumors. Rev Endocr Metab Disord 2018, 19(2)179-192.
IF: 5. 516
Q: 1

Jimenez-Lucena R, Camargo A, Alcala-Diaz JF, Romero-Baldonado C, Luque RM, van Ommen B, Delgado-Lista J, Ordovas JM, Perez-Martinez P, Rangel-Zuniga OA, Lopez-Miranda J. A plasma circulating miRNAs profile predicts type 2 diabetes mellitus and prediabetes: from the CORDIOPREV study. Exp Mol Med 2018, 50(12):168.
IF: 4.743
Q: 1

Leon-Gonzalez AJ, Navarro I, Acero N, Mingarro DM, Martin-Cordero C. Genus Retama: a review on traditional uses, phytochemistry, and pharmacological activities. Phytochem Rew 2018, 17(4)701-731.
IF: 4.257
Q: 1   D: 1

Gomez-Gomez E, Rosa JV, Valiente JC, Tarradas FT, Curado FA, Ruiz DL, Tapia MJ. New Approach to Guide Target Prostate Biopsy: Technique and Initial Experience. Urology 2018, 121()198-199.
IF: 1.861
Q: 2   

Cordoba-Chacon J, Sarmento-Cabral A, del Rio-Moreno M, Diaz-Ruiz A, Subbaiah PV, KinemanRD. Adult-Onset Hepatocyte GH Resistance Promotes NASH in Male Mice, Without Severe Systemic Metabolic Dysfunction. Endocrinology 2018, 159(11)3761-3774.
IF: 3.800
Q: 2    

Salamanca-Bustos JJ, Gomez-Gomez E, Campos-Hernandez JP, Carrasco-Valiente J, Ruiz-Garcia J, Marquez-Lopez FJ, Zurera-Tendero L, Requena-Tapia MJ. Initial Experience in the Use of Novel Auto-expandable Metal Ureteral Stent in the Treatment of Ureter Stenosis in Kidney Transplanted Patients. Transplantation Proceedings 2018, 50(2)587-590.
IF: 0.959
Q: 4

Main Publications 2017

Hormaechea-Agulla D, Gahete MD, Jimenez-Vacas JM, Gomez-Gomez E, Ibanez-Costa A, L-Lopez F, Rivero-Cortes E, Sarmento-Cabral A, Valero-Rosa J, Carrasco-Valiente J, Sanchez-Sanchez R, Ortega-Salas R, Moreno MM, Tsomaia N, Swanson SM, Culler MD, Requena MJ, Castaño JP, Luque RM. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness. MOLECULAR CANCER. 2017. 16(1):146.
IF: 6,204
Q: 1 

Hormaechea-Agulla D, Jimenez-Vacas JM, Gomez-Gomez E, Lopez FL, Carrasco-Valiente J, Valero-Rosa J, Moreno MM, Sanchez-Sanchez R, Ortega-Salas R, Gracia-Navarro F, Culler MD, Ibanez-Costa A, Gahete MD, Requena MJ, Castaño JP, Luque RM. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer. FASEB JOURNAL. 2017. 31(11): 4682-4696.
IF: 5,498
Q: 1  D: 1

Luque RM, Lopez-Sanchez LM, Villa-Osaba A, Luque IM, Santos-Romero AL, Yubero-Serrano EM, Cara-Garcia M, Alvarez-Benito M, Lopez-Miranda J, Gahete MD, Castaño JP. Breast cancer is associated to impaired glucose/insulin homeostasis in premenopausal obese/overweight patients. ONCOTARGET. 2017. 8(46):81462-81474.
IF: 5,168
Q: 1 

Sarmento-Cabral A, L-Lopez F, Gahete MD, Castaño JP, Luque RM. Metformin reduces prostate tumor growth, in a diet-dependent manner, by modulating multiple signaling Pathways. MOLECULAR CANCER RESEARCH. 2017. 15(7):862-874.
IF: 4,974
Q: 1 

L-Lopez F, Sarmento-Cabral A, Herrero-Aguayo V, Gahete MD, Castaño JP, Luque RM. Obesity and metabolic dysfunction severely influence prostate cell function: role of insulin and IGF1. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2017. 21(9):1893-1904.
IF: 4,499
Q: 1 

Herrera-Martinez AD, Gahete MD, Sanchez-Sanchez R, Salas RO, Serrano-Blanch R, Salvatierra A, Hofland LJ, Luque RM, Galvez-Moreno MA, Castaño JP. The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features. LUNG CANCER. 2017. 109:128-136.
IF: 4,294
Q: 1 

Sarmento-Cabral A, L-Lopez F, Luque RM. Adipokines and their receptors are widely expressed and distinctly regulated by the metabolic environment in the prostate of male mice: Direct role under normal and tumoral conditions. ENDOCRINOLOGY. 2017. 158(10):3540-3552.
IF: 4,283
Q: 1 

Ibanez-Costa A, Lopez-Sanchez LM, Gahete MD, Rivero-Cortes E, Vazquez-Borrego MC, Galvez MA, de la Riva A, Venegas-Moreno E, Jimenez-Reina L, Moreno-Carazo A, Tinahones FJ, Maraver-Selfa S, Japon MA, Garcia-Arnes JA, Soto-Moreno A, Webb SM, Kineman RD, Culler MD, Castaño JP, Luque RM. BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas. SCIENTIFIC REPORTS. 2017. 7():42002.
IF: 4,259
Q: 1 

Sarmento-Cabral A, Peinado JR, Halliday LC, Malagón MM, Castaño JP, Kineman RD, Luque RM. Adipokines (Leptin, Adiponectin, Resistin) differentially regulate all hormonal cell types in primary anterior pituitary cell cultures from two primate species. SCIENTIFIC REPORTS. 2017. 7:43537.
IF: 4,259
Q: 1 

Pedraza-Arévalo S, Hormaechea-Agulla D, Gomez-Gomez E, Requena MJ, Selth LA, Gahete MD, Castaño JP, Luque RM. Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer. PROSTATE. 2017. 77(15):1499-1511.
IF: 3,82
Q: 1 

Ibanez-Costa A, Luque RM, Castaño JP. Cortistatin: A new link between the growth hormone/prolactin axis, stress, and metabolism. GROWTH HORMONE & IGF RESEARCH. 2017. 33:23-27.
IF: 1,828
Q: 4 

Members

Dr. Manuel David Gahete Ortiz

Co-Principal Investigator

Team

Manuel David Gahete Ortiz, Antonio José León González, Mercedes del Río Moreno, María del Carmen Vázquez Borrego, Juan Manuel Jiménez Vacas, Emilia María Alors Pérez, Enrique Gómez Gómez, Vicente Herrero Aguayo, Prudencio Sáez Martínez, Juan Luis López Cánovas, Rafael Sánchez Sánchez, María Teresa Sánchez Medianero, Álvaro Toledano Borrego, Fernando López López, Antonio Jesús Montero Hidalgo, Jesús Miguel Pérez Gómez, André Morais Sarmento Borges Cabral, Jesús Delgado Luque, Antonio Jesús Martínez Fuentes, Trinidad Moreno Montilla